To Identify An Enzyme Or Isoenzyme Patents (Class 435/7.4)
  • Publication number: 20150093378
    Abstract: Disclosed herein are methods for treating type 2 diabetes, limiting development of type 2 diabetes, and treating a pre-diabetic state by administering to a subject in need thereof a GPBP inhibitor. Also disclosed herein are methods for diagnosing a pre-diabetic state and for diagnosing a propensity to develop type 2 diabetes by determining an amount of GPBP in a sample from a subject and comparing to control.
    Type: Application
    Filed: September 26, 2014
    Publication date: April 2, 2015
    Inventors: Juan SAUS, Fernando REVERT, Francisco REVERT-ROS
  • Publication number: 20150093373
    Abstract: The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 2, 2015
    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventor: Edward C. DEMPSEY
  • Publication number: 20150093758
    Abstract: Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively.
    Type: Application
    Filed: July 28, 2014
    Publication date: April 2, 2015
    Inventors: James R. Heath, Heather Dawn Agnew, Suresh Mark Pitram
  • Publication number: 20150093329
    Abstract: The invention provides methods and products, such as kits, useful for determining the apoptotic state of cells in an organism, comprising detecting the presence or abundance of at least one caspase affinity labeling agent in the cells of an animal into which at least one caspase affinity labeling agent has been introduced, wherein the presence or abundance of the caspase affinity labeling agent correlates with the apoptotic state of the cells.
    Type: Application
    Filed: September 12, 2014
    Publication date: April 2, 2015
    Applicant: SEED RESEARCH AND DEVELOPMENT, LLC
    Inventors: Gary Johnson, Brian W. Lee
  • Publication number: 20150093759
    Abstract: Antibodies for detecting nitration of nitrotyrosine 247 PKG-1? and antibodies for detecting nitrotyrosine 425 of PKG-1? are disclosed. Methods of detecting nitrotyrosine 247 PKG-1? and nitrotyrosine 425 of PKG-1?, and uses thereof are also disclosed for identification and diagnosis or phenotypes, pathologies, diseases and disorders associated with protein nitration of PKG-1? are also disclosed. In a preferred embodiment, one or more of the disclosed antibodies is used in the disclosed methods.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 2, 2015
    Inventor: Stephen M. Black
  • Publication number: 20150094215
    Abstract: A reverse transcriptase encoded by L-1 (LINE-1) has been identified as a target molecule for treating or preventing cancers induced or mediated by this molecule. Method of treating or preventing such cancers in patients involves administration of a therapeutically effective amount of a composition having an inhibitor or antagonist of the reverse transcriptase in cells of the patients. The inhibitor or antagonist blocks lengthening of telomeres in telomerase negative cells. Methods and kits for detecting pathologically proliferating cells expressing L1RT are also disclosed.
    Type: Application
    Filed: July 14, 2014
    Publication date: April 2, 2015
    Inventors: Igor E. BONDAREV, John S. BERTRAM
  • Publication number: 20150094225
    Abstract: Provided are a method of obtaining information for identifying tumor cells undergoing epithelial-mesenchymal transition in a sample, a method of identifying tumor cells undergoing epithelial-mesenchymal transition in a sample, a method of diagnosing a subject having a tumor, and a composition or kit for identifying tumor cells undergoing epithelial-mesenchymal transition in a sample.
    Type: Application
    Filed: October 1, 2014
    Publication date: April 2, 2015
    Inventors: Yeonjeong Kim, Kyungyeon Han, Yousun Kim, Donghyun Park, Jungwon Keum, Jongmyeon Park
  • Publication number: 20150093389
    Abstract: The present invention relates to recombinant Clostridium difficile antigens based on a polypeptide, consisting of or comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence consisting of residues 1500-700 of a C. difficile Toxin A sequence or a C. difficile Toxin B sequence; though with the proviso that the polypeptide does not include one or more Repeat Unit (RU) located between amino acid residues 1851-2710 of C. difficile Toxin A and/or residues 1853-2366 of a C. difficile Toxin B protein that consists of or comprises a first amino acid sequence and a second amino acid. Also provided is the use of said antigens for the prevention/treatment/suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/treatment/suppression of CDI.
    Type: Application
    Filed: April 4, 2013
    Publication date: April 2, 2015
    Applicant: The Secretary of State for Health
    Inventors: Clifford Shone, April Roberts, Michael Maynard-Smith
  • Patent number: 8993231
    Abstract: The present invention relates to methods for rapidly expanding a stem cell population with or without culture supplements in simulated microgravity conditions. The present invention relates to methods for rapidly increasing the life span of stem cell populations without culture supplements in simulated microgravity conditions. The present invention also relates to methods for increasing the sensitivity of cancer stem cells to chemotherapeutic agents by culturing the cancer stem cells under microgravity conditions and in the presence of omega-3 fatty acids. The methods of the present invention can also be used to proliferate cancer cells by culturing them in the presence of omega-3 fatty acids. The present invention also relates to methods for testing the sensitivity of cancer cells and cancer stem cells to chemotherapeutic agents by culturing the cancer cells and cancer stem cells under microgravity conditions.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: March 31, 2015
    Assignee: Marshall University Research Corporation
    Inventors: Pier Paolo Claudio, Jagan V. Valluri
  • Publication number: 20150087605
    Abstract: Disclosed are compositions and methods for treating anthrax, inhibiting anthrax toxins and inhibiting anthrax toxin-induced cytotoxicity. Carboxylic acid-containing small molecules can be used in the methods and compositions disclosed herein, for example, sulindac and derivatives thereof may be used. Methods of screening for carboxylic acid-containing small molecules that can be used to treat anthrax are disclosed. Targeting the anthrax toxin reduces the risks of anthrax spores.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 26, 2015
    Inventors: J. Manuel Perez Figueroa, Oscar Santiesteban, Charalambos Kaittanis
  • Publication number: 20150086509
    Abstract: The present invention provides for methods and compositions for treating cancer. A subject having cancer is administered an interferon and an inhibitor of mitogen-activated protein kinase (MAPK) signaling pathway. The combination of the interferon and the inhibitor of the MAPK pathway produces a synergistic effect on the cancer compared to the effect of the interferon or the inhibitor of the MAPK pathway alone. The activity of the interferon pathway, interferon expression levels and/or interferon locus copy number can be used as biomarkers for treatment of cancer by MAPK pathway inhibitors.
    Type: Application
    Filed: September 25, 2014
    Publication date: March 26, 2015
    Inventors: Oren Litvin, Neal Rosen, Dana Pe'er
  • Publication number: 20150087541
    Abstract: The present invention is based in part on a chemically defined method of generating neural stem cells (NSCs) and dopaminergic (DA) neurons from human pluripotent stem cells (hPSCs). The DA neurons of the invention can be derived from hPSCs and NSCs. The present invention also provides reagents and kits useful for the derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells.
    Type: Application
    Filed: April 23, 2013
    Publication date: March 26, 2015
    Inventors: Rodolfo Gonzalez, Ibon Garitaonandia, Ruslan Semechkin
  • Publication number: 20150086998
    Abstract: Value-assigned solutions having predetermined concentrations of recombinant Lp-PLA2 are described herein. In particular, described herein are solutions of rLp-PLA2 that are stable for an extended period of time. Kits and assays include these calibration solutions, as well as methods of making and using them are described.
    Type: Application
    Filed: May 15, 2014
    Publication date: March 26, 2015
    Inventors: Thomas D. SCHAAL, Shaoqiu Zhuo
  • Publication number: 20150086570
    Abstract: The present invention relates to biomarkers for use in determining the sensitivity of patients to therapy with ?v?6 integrin inhibition or therapy with TGF-? pathway inhibitors. The biomarker profiles disclosed herein provide individualized gene and protein profiles which will aid in treating diseases and disorders which are amenable to treatment with therapies designed against ?v?6-integrin and/or TGF-? pathway inhibitors.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 26, 2015
    Inventors: Shelia M. Violette, Dean Sheppard
  • Publication number: 20150086974
    Abstract: A problem to be solved by the present invention is to provide an immunochromatographic test strip and a detection method using immunochromatography avoiding aggregation of colloidal gold conjugates while red blood cells in whole blood are agglutinated and then separated and removed in the case of using polybrene as a blood-agglutinating agent and the colloidal gold conjugates as a detection reagent. To solve the problem, the present inventers reviewed a past reagent configuration itself from a completely different viewpoint rather than selecting type and amount of polyanions and, as a result of extensive study on each element, the inventers surprisingly found that aggregation of colloidal gold can be suppressed by using a certain buffer solution without using neutralization by polyanions.
    Type: Application
    Filed: April 1, 2013
    Publication date: March 26, 2015
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Mayumi Yoshida, Mitsuaki Yamamoto, Shinya Yokokawa, Tomo Shimizu, Keigo Kono
  • Publication number: 20150086999
    Abstract: Long shelf-life kits, value-assigned solutions, and methods for standardizing, verifying, calibrating or recalibrating detection of lipoprotein-associated phospholipase A2 having using them are described herein. In particular, described herein are methods of using solutions of rLp-PLA2 that are stable for an extended period of time to standardize, verify, calibrate or recalibrate assays for Lp-PLA2.
    Type: Application
    Filed: May 15, 2014
    Publication date: March 26, 2015
    Inventors: Thomas D. SCHAAL, Erhard Ralf SCHOENBRUNNER, Shaoqiu Zhuo
  • Publication number: 20150079607
    Abstract: The present invention relates to methods useful to monitor central and peripheral nervous system neuron/axon destruction resulting from an increase in acute phase inflammatory enzymes. The methods have applicability to monitoring the progress of neurological diseases, including multiple sclerosis and Alzheimer's disease, as well as neuroinflammatory damage that results from sports injuries, vigorous physical activity or any form of physical abuse. The invention further relates to methods of treating multiple sclerosis or other diseases with an inflammatory component related to phospholipase A2.
    Type: Application
    Filed: June 5, 2014
    Publication date: March 19, 2015
    Applicant: Philadelphia Health and Education Corporation, d/b/a Drexel University College of Medicine
    Inventors: Timothy J. Cunningham, Lihua Yao
  • Publication number: 20150078996
    Abstract: The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 19, 2015
    Inventors: Liliane Goetsch, David Brooks, Michael Chastain, Zhi-Qiang Zhang, Nathalie Corvaia
  • Publication number: 20150079111
    Abstract: Mechanisms for complications of renal failure and processes for treating the same are disclosed. They include contacting a biological fluid (e.g. blood) with a filter body, the filter body having immobilized thereon either a CD36 receptor or a CD36 receptor fragment or a SCARB1 receptor or a SCARB1 receptor fragment, the blood having a reduced quantity of oxidatively modified proteins after contacting the filter body. They also include administering an antagonist drug to a patient that blocks the binding activity of the RAGE receptor or the CD36 receptor or the SCARB1 receptor. Diagnostic methods are also provided.
    Type: Application
    Filed: June 5, 2013
    Publication date: March 19, 2015
    Inventor: Jonas AXELSSON
  • Publication number: 20150082467
    Abstract: The present invention relates to; a pharmaceutical compostion capable of enhancing immunity against viruses by specifically decreasing the expression of the OASL1 protein; and a method for screening for a material capable of being used as an antiviral agent by comparing the amount of expression of the OASL1 protein.
    Type: Application
    Filed: February 13, 2013
    Publication date: March 19, 2015
    Inventors: Young-Joon Kim, Myeong Sup Lee, Byungil Kim, Goo Taeg Oh
  • Publication number: 20150080254
    Abstract: The present invention relates to novel lateral flow devices using two dimensional features, preferably, uniform two dimensional test and control signal readout patterns, and the methods for detecting an analyte using the lateral flow devices.
    Type: Application
    Filed: September 12, 2014
    Publication date: March 19, 2015
    Inventors: Brendan O'FARRELL, Thomas C. TISONE
  • Publication number: 20150079107
    Abstract: Provided herein are methods and assays for isolating and culturing seborrheic keratosis cells ex vivo. Also provided herein are screening assays using cultured seborrheic keratosis cells and methods for treating seborrheic keratosis in a subject.
    Type: Application
    Filed: April 26, 2013
    Publication date: March 19, 2015
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Anna I. Mandinova, Sam W. Lee, Victor A. Neel
  • Publication number: 20150080302
    Abstract: The present invention relates to new therapeutic and diagnostic uses of soluable neuregulin-1 isoforms and polypeptides, particularly neurological disorders.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Thierry Baussant, Daniel Bach, André Schrattenholz
  • Publication number: 20150080463
    Abstract: Methods are provided for diagnosing the risk of a cardiovascular event in a patient. In some embodiments, the method includes measuring the level of proprotein convertase subtilisin kexin type 9 (PCSK9) in a sample obtained from a patient and comparing the measured level of PCSK9 to a control. Also provided are methods of selecting a therapy for a patient prior to administration of the therapy. In some embodiments, the method includes measuring a PCSK9 blood concentration in a sample from a patient to determine the presence or absence of a PCSK9 blood concentration indicative of responsiveness to an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Further provided are methods for assessing the efficacy of a therapy being administered to a patient. In certain embodiments, the method includes detecting a change in a PCSK9 blood concentration in a sample from a patient, wherein a change in detected levels is indicative of whether the therapy is efficacious.
    Type: Application
    Filed: March 16, 2011
    Publication date: March 19, 2015
    Applicant: BG MEDICINE, INC.
    Inventor: Pieter Muntendam
  • Publication number: 20150072881
    Abstract: The present invention relates to methods to objectively assess treatment outcomes in Reward Deficiency Syndrome (RDS) behaviors by obtaining expression profiles (e.g., mRNA expression and/or protein expression profiles) for one or more genes at two or more different time points, for example, before and after treating a subject known to have or suspected of having an RDS affliction. Analysis, for example, of mRNA and/or protein expression levels and/or patterns can be conducted before admission to a treatment facility, followed by testing at one or more various designated times during and after a subject's treatment. Such methods may also be combined with other tests, and can be used in diagnosis and treatment of RDS and RDS behaviors, including drug and/or alcohol abuse and addiction, overeating, gambling, sexual addiction, etc.
    Type: Application
    Filed: April 7, 2014
    Publication date: March 12, 2015
    Inventor: Kenneth BLUM
  • Publication number: 20150072355
    Abstract: Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal.
    Type: Application
    Filed: October 31, 2014
    Publication date: March 12, 2015
    Inventors: Norbert Wild, Marie-Luise Hagmann, Johann Karl, Julia Riedlinger, Markus Roessler, Michael Tacke
  • Publication number: 20150071933
    Abstract: Annexin A3 (ANAX3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (HCC) and the utilization of a monoclonal antibody against ANXA3 or antisense polynucleotide against ANXA3 mRNA for the suppression or treatment of HCC, alone or in combination with other HCC treatment. Monoclonal antibody against ANXA3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance.
    Type: Application
    Filed: September 12, 2014
    Publication date: March 12, 2015
    Inventors: Stephanie Kwai Yee Ma, Man Tong, Xin-Yuan Guan
  • Publication number: 20150064715
    Abstract: The present invention provides methods of detecting mitochondrial dysfunction or acute kidney injury (AKI) by measuring the urinary protein levels of the ATP synthase (ATPS) beta subunit or cleavage products thereof in a subject.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 5, 2015
    Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Rick SCHNELLMANN, John ARTHUR, Craig BEESON
  • Publication number: 20150064136
    Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Applicant: The University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Larisa Geskin, Oleg E. Akilov
  • Publication number: 20150064714
    Abstract: Labelled polypeptide constituted by: (i) a peptide fragment of 38 to 50 amino acids including a peptide of sequence SEQ ID NO: 1, and (ii) a label selected from the group constituted by radioactive groups, non-protein fluorophors, protein fluorophors, magnetic particles or a paramagnetic spin label, in order that when the label is a fluorophor protein, the labelled polypeptide further contains a peptide spacer of 3 to 15 amino acids, located between the peptide fragment and the label and use thereof as a diagnostic tool.
    Type: Application
    Filed: December 3, 2013
    Publication date: March 5, 2015
    Applicant: LIFESEARCH
    Inventor: Tiona ANDRIANAIVOMANANJAONA
  • Publication number: 20150064716
    Abstract: The present invention provides native Goodpasture antigen binding protein isoforms, monoclonal antibodies directed against such proteins, and methods for their use.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 5, 2015
    Inventors: Juan Saus, Fernando Revert
  • Publication number: 20150065380
    Abstract: The present invention relates to epilepsy-inducing brain somatic mutations which are associated with intractable epilepsy caused by malformations of cortical development, and uses thereof. More particularly, the present invention relates to an mTOR (Mammalian target of rapamycin) gene having mutations in a nucleotide sequence or an mTOR protein having mutations in an amino acid sequence resulting from the mutations in the nucleotide sequence. Further, the present invention relates to a technique for diagnosing intractable epilepsy caused by malformations of cortical development using the gene or the protein.
    Type: Application
    Filed: September 2, 2014
    Publication date: March 5, 2015
    Inventors: Jeong Ho LEE, Dong Seok Kim, Hoon Chul Kang, Jae Seok Lim, Woo-II Kim
  • Patent number: 8969022
    Abstract: The invention provides a method and system for developing and using diagnoses of lymphosarcoma in feline subjects using thymidine kinase (TK) and haptoglobin (HP) as biomarkers. The invention provides a method for obtaining the level of each biomarker and computing an index for a feline subject. The invention provides predefined index ranges to which the index value may be matched in order to determine whether the subject has a high probability of being affected by lymphosarcoma, even when the subject shows apparent symptoms that may be common with inflammatory bowel disease.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: March 3, 2015
    Assignee: Veterinary Diagnostics Institute, Inc
    Inventor: Randy Ringold
  • Publication number: 20150057180
    Abstract: Provided are methods and kits for analyzing biomarkers in one or more signal transduction pathways in a cell. In some embodiments, the methods and kits of the invention permit simultaneous analysis of more than one biomarker and/or more than one signal transduction pathway. In some embodiments, the invention provides methods for detecting whether a cell treated with an agent targeting a targeted biomarker is responding to the agent, or whether the cell is developing resistance to the agent. In some embodiments, the invention provides methods for determining which biomarker to target in a diseased or damaged cell, or which pathway an agent is targeting in an agent-treated cell. The invention provides kits for carrying out the described methods.
    Type: Application
    Filed: September 5, 2014
    Publication date: February 26, 2015
    Inventors: Edward Marshall Alderman, Matthew William Dickerson, Lee Anne Beausang, Brett Peter Masters, Martin Latterich
  • Publication number: 20150056190
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Priti Hegde, Maike Schmidt, Ru-Fang Yeh
  • Publication number: 20150057350
    Abstract: Methods and systems for using fibrosis biomarkers associated with a prolonged period of physical inactivity are provided. Also provided is a method of reducing the effect of prolonged physical inactivity on the development of fibrosis in a subject who is experiencing or is expected to experience prolonged physical inactivity in the near future by administering a therapeutically effective amount of a leucine metabolite (e.g., ?-hydroxy-?-methylbutyric acid (HMB)) to the subject.
    Type: Application
    Filed: August 21, 2014
    Publication date: February 26, 2015
    Applicant: ABBOTT LABORATORIES
    Inventors: SUZETTE PEREIRA, MENGHUA LUO, NEILE EDENS, GERARD DAVIS, SUSAN GAWEL, RAJ CHANDRAN
  • Publication number: 20150056633
    Abstract: The present invention, in some aspects, relates to systems and methods for determining oxidized proteins, including glutathionylated proteins such as S-glutathionylated proteins. The systems and methods of the invention can be used in vitro (e.g., in cell or tissue culture) or in vivo, for example, to diagnose a person having an oxidative stress condition. For instance, in some cases, the invention can be used to spatially determine the location and/or concentration of oxidized proteins within cells and/or tissues (e.g., through visual detection). In one set of embodiments, a glutathionylated or otherwise oxidized moiety on a protein may be reacted with a detection entity, which may be, for example, fluorescent, radioactive, electron-dense, able to bind to a signaling entity or a binding partner in order to produce a signal, etc.
    Type: Application
    Filed: September 18, 2014
    Publication date: February 26, 2015
    Applicants: The University of Vermont and State Agricultural College, Universiteit Maastricht
    Inventors: Yvonne M. Janssen-Heininger, Niki Reynaert
  • Publication number: 20150056137
    Abstract: Provided is an activatable probe that undergoes intramolecular cyclization and subsequent aggregation in apoptotic tumor cells upon peptidase-initiated, and most advantageously caspase-3, activation. These caspase-sensitive nano-aggregation probes (C-SNAFs) are generally biocompatible, possess NIR spectral properties or may serve as PET or MRI imaging agents, and have a mechanism of target-mediated nanostructure self-assembly amenable to in vivo use. The probes encompass biocompatible condensation chemistry products that comprise D-cysteine and 2-cyano-6-hydroxyquinoline (CHQ) moieties linked to an amino-luciferin scaffold, and which can be activated by a two-step reaction requiring caspase-3/7-mediated cleavage of an aspartate-glutamate-valine-aspartate (L-DEVD) capping peptide and the free intracellular thiol-mediated reduction of the disulfide bond.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 26, 2015
    Inventors: Jianghong Rao, Deju Ye, Adam Shuhendler, Frederick Te-Ning Chin, Jongho Jeon, Bin Shen
  • Patent number: 8962266
    Abstract: The present invention provides compounds and methods for assaying activities of enzymes such as histone deacetylases and histone acetyltransferases. In some embodiments, the methods may be performed in one step. The compounds described herein features peptide-based compounds having at least one blocked lysine or arginine residue which are coupled to reporter moieties. The methods described herein involve reacting a compound described herein with an enzyme, such as a histone deacetylase enzyme or a histone acetyltransferase enzyme, and an endopeptidase that recognizes basic amino acids to release the reporter moiety which may be subsequently detected.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: February 24, 2015
    Assignee: Promega Corporation
    Inventors: Thomas Kirkland, Andrew L. Niles, Martha O'Brien, Carolyn Woodroofe Hitko
  • Patent number: 8962265
    Abstract: Cloning and characterization of a TgIF2? kinase from Toxoplasma gondii designated TgIF2K-D illustrates that this protein is related to GCN2, an eIF2? kinase known to respond to nutrient starvation in other organisms. TgIF2K-D is present in the cytosol of both intra- and extracellular Toxoplasma and facilitates translational control through TgIF2? phosphorylation in extracellular parasites. Both a TgIF2K-D knockout parasite and a parasite harboring the TgIF2? mutant (S71A substitution) exhibited loss of eIF2? kinase activity which manifested itself as significant fitness defect. Accordingly, eIF2? phosphorylation and translational control are an important mechanism by which vulnerable extracellular parasites protect themselves which searching for a new host cell. TgIF2K-D is an excellent target for development of compounds and therapies that can be used to treat infections caused by Toxoplasma and other eukaryotic parasites, especially parasites that have high homology or identity to TgIF2K-D.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: February 24, 2015
    Assignee: Indiana University Research and Technology Corp.
    Inventors: William J. Sullivan, Jr., Ronald C. Wek
  • Patent number: 8962239
    Abstract: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: February 24, 2015
    Assignees: Opko Renal, LLC, Opko IP Holdings II, Inc.
    Inventors: P. Martin Petkovich, Christian F. Helvig, Joel Z. Melnick
  • Publication number: 20150050664
    Abstract: A method of preparing a sample for conducting an assay, the method including: providing an input sample including glycoproteins; capturing glycoproteins from the input sample on a solid support; and washing the sample support to remove unbound portions of the input sample.
    Type: Application
    Filed: May 9, 2012
    Publication date: February 19, 2015
    Applicant: ADVANCED LIQUID LOGIC, INC.
    Inventors: Carrie Graham, Allen Eckhardt, Lisa Perkins
  • Publication number: 20150051288
    Abstract: Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder.
    Type: Application
    Filed: October 10, 2014
    Publication date: February 19, 2015
    Inventors: Paul Talalay, Andrew W. Zimmerman, Kirby D. Smith
  • Publication number: 20150051110
    Abstract: Provided herein are compositions and methods for identifying and detecting modulators of Ras protein conformational states through the use of second harmonic generation (SHG) technology. Also provided herein are methods for detecting a conformational changes in the three dimensional structure of a protein bound to a supported lipid bilayer.
    Type: Application
    Filed: November 2, 2012
    Publication date: February 19, 2015
    Inventors: Joshua S. Salafsky, Ryan P. McGuinness
  • Publication number: 20150050274
    Abstract: The present invention relates to methods and biomarkers for detection and characterization of mature T-cell neoplasias/leukemias (e.g., T-cell prolymphocytic leukemia, Sezary syndrome) in biological samples (e.g., tissue samples, blood samples, plasma samples, cell samples, serum samples).
    Type: Application
    Filed: August 14, 2014
    Publication date: February 19, 2015
    Inventors: Kojo Elenitoba-Johnson, Mark J. Kiel, Thirunavukkarasu Velusamy, Anagh Sahasrabuddhe, Delphine Rolland, Megan Lim
  • Publication number: 20150050289
    Abstract: Agents, compositions, and medicaments that pertain to modulating the activity of muscle specific kinase receptor (MuSK) and methods and uses thereof to modulate MuSK activity are encompassed herein. Also encompassed are screening assays to identify modulators of MuSK activity. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to alleviate or delay motor dysfunction in subjects afflicted with a disorder associated with nerve terminal loss or fragmentation, such as amyotrophic lateral sclerosis, sarcopenia, or anti-MuSK myasthenia gravis.
    Type: Application
    Filed: November 14, 2012
    Publication date: February 19, 2015
    Inventor: Steven J. Burden
  • Publication number: 20150050666
    Abstract: Disclosed is a non-specific reaction inhibitor for use in an immunological measurement, comprising a complex of an antibody or a fragment of the antibody capable of specifically binding to a non-specific reaction factor, and a polymer. The non-specific reaction inhibitor can inhibit a non-specific reaction which may interfere with the accurate detection or quantification of a trace substance in an immunological measurement method.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 19, 2015
    Inventors: Yoshikazu Takagi, Yuichi Shintani
  • Publication number: 20150051115
    Abstract: The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injuries. Brain injury can include overt or traumatic brain injury, as well as subclinical brain injury (SCI). In one embodiment, a method for diagnosing SCI in a patient comprises (a) collecting a sample from the patient, (b) measuring the levels of a panel of biomarkers in the sample collected from the patient, wherein the panel of biomarkers comprises ASTN1, BAI3, CNDP1, ERMIN, GFAP, GRM3, KLH32, MAGE2, NRG3, NRGN, OMG, SLC39A12, RTN1, and MT3; and (c) comparing the levels of the panel of biomarkers with predefined levels of the same panel of biomarkers than correlate to a patient having SCI and predefined levels of the same panel of biomarkers that correlate to a patient not having SCI, wherein a correlation to one of the predefined levels provides the diagnosis.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 19, 2015
    Inventors: Allen Dale Everett, James Francis Casella, Jennifer van Eyk
  • Publication number: 20150050665
    Abstract: The invention relates to compositions and methods for detecting, screening, diagnosing or determining the progression of, regression of and/or survival from a proliferative disease or condition, specifically breast cancer. The invention also provides new assays and kits for the staging or stratifying breast cancer patients or patients suspected of having breast cancer.
    Type: Application
    Filed: October 17, 2014
    Publication date: February 19, 2015
    Inventor: Patrick J. Muraca
  • Publication number: 20150045284
    Abstract: The present invention relates to crystals of a type IB P-type ATPase having the space group P1 and methods for purification and growing said crystals. The invention also presents methods for identifying an inhibitor of a type IB P-type ATPase for example by determining binding interactions between an inhibitor and a set of binding interaction sites in said type IB P-type ATPase.
    Type: Application
    Filed: January 20, 2012
    Publication date: February 12, 2015
    Applicant: Aarhus Universitet
    Inventors: Poul Nissen, Pontus Gourdon, Xiang Liu, Bjorn Panyella Pedersen, Daniel Mattle